pomalidomide / Generic mfg. - LARVOL DELTA

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "The significantly improved overall survival and patient-reported measures in CARTITUDE-4 reinforce the use of cilta-cel in treating relapsed or refractory multiple myeloma as early as after first relapse."

Journal • P3 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology

Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study. (PubMed, Haematologica) - P2 | "Refractoriness rates to bortezomib, lenalidomide and daratumumab were 51%, 85% and 96% respectively. To conclude, the all-oral IPd regimen for TCE RRMM patients showed high response rates and a manageable safety profile, in a cohort enriched with TCR, elderly and frail patients. (NCT04790474)."

Clinical • Journal • P2 data • Hematological Malignancies • Multiple Myeloma • Oncology

CERVINO: A Randomized Phase 3 Study of Etentamig vs Investigator's Choice of Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Triple-Class Exposure (IMS 2026) - P3 | "Pts were randomized 1:1 to Etenta Q4W or SAT (carfilzomib + dexamethasone [Kd], elotuzumab + pomalidomide + d [EloPd], or selinexor + bortezomib + d [SVd]). In heavily pretreated pts with triple-class exposed RRMM, Etenta significantly improved ORR and PFS vs SAT, with an early positive OS signal. A single SUD andQ4Wdosing from initiation were associated with very low rates of CRS, ICANS, and ≥ G3 infections, reinforcing Etenta’s best-in-class safety potential. Data support Etenta monotherapy as a new standard of care with convenient dosing suitable for global outpatient and community use."

Clinical • Late-breaking abstract • P3 data • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Cevostamab Plus Pomalidomide (Pom) and Dexamethasone (Dex) Induces Durable Remissions in BCMA-Naïve Patients With Relapsed/Refractory Multiple Myeloma (RRMM): CAMMA 1 Arm B Extended Follow-up Data (IMS 2026) - P1 | "Cevostamab plus pom-dex induces durable remissions in BCMA-naïve pts with RRMM. Updated data will be presented."

Clinical • IO biomarker • Cerebral Hemorrhage • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Septic Shock • Thrombocytopenia • GPRC5D

Projecting Functional Cure in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) in the MajesTEC-3 Study of Teclistamab-Daratumumab (Tec-Dara) Using a Mixture Cure Model (IMS 2026) - P3 | "Introduction: In the phase 3 MajesTEC-3 study (NCT05083169) , Tec-Dara significantly improved progression-free survival (PFS; HR 0.17; 95% CI 0.12–0.23) and overall survival (OS; HR 0.46; 95% CI 0.32–0.65) vs Dara plus dexamethasone with pomalidomide or bortezomib (DPd/DVd) in pts with RRMM and 1–3 prior lines of therapy ( median follow-up 34.5 mo) . Best fit models estimated >85% cure fractions for OS and PFS in Tec-Dara pts in MajesTEC-3. While functional cure does not imply biological/clinical cure, the analysis suggests that a substantial fraction of Tec-Dara-treated pts will experience a mortality risk and projected life expectancy similar to the general population. MajesTEC-3 is ongoing, and if continued follow-up confirms the model-based predictions, Tec-Dara may help redefine survival expectations in RRMM"

Clinical • Hematological Malignancies • Multiple Myeloma

Overall Survival, Progression and Non-Relapse Mortality With Teclistamab Plus Daratumumab (Tec-Dara) vs Dara-Based Triplets in Relapsed/Refractory Multiple Myeloma (RRMM): MajesTEC-3 Post Hoc Analysis (IMS 2026) - "Introduction: Tec-Dara showed significant survival benefits vs Dara + dexamethasone + pomalidomide/bortezomib (DPd/DVd) in MajesTEC-3 in early-line RRMM, a setting in which disease progression is the leading cause of death... Patients (pts) had 1–3 prior lines of therapy (LOT), including a proteasome inhibitor and lenalidomide (len; len-refractory if 1 prior LOT) with progression on/after last LOT... Tec-Dara significantly improved OS over DPd/DVd in pts with RRMM and 1–3 prior LOT. This analysis demonstrates that the observed OS benefit is driven by a profound reduction in disease progression, the leading cause of mortality in RRMM. Despite early curve crossing, Tec-Dara did not increase NRM."

Clinical • Retrospective data • Hematological Malignancies • Multiple Myeloma

Etentamig Combined With Pomalidomide Plus Dexamethasone (Pom+Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) After 1-3 Prior Lines of Therapy: A Phase 1b Dose-Escalation and Safety Expansion Study (IMS 2026) - P1 | " Arm E of this multi-arm, open-label, multicenter, Phase 1b dose-escalation and -expansion study enrolled pts ≥18 years old with RRMM after 1–3 PLT, including lenalidomide. Consistent with the previously reported Arm A data, the etentamig plus pom+dex combination led to deep responses. Considering the shorter Arm E follow-up time, the introduction of a single SUD, as well as delayed pom administration in Arm E, further reduced CRS and infection risk, mirroring etentamig monotherapy rates. These data support further exploration of the regimen in a randomized Phase 3 study."

Clinical • P1 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia

Randomized phase II trial of liposomal cytarabine and daunorubicin with or without pomalidomide in newly diagnosed acute myeloid leukemia myelodysplasia-related. (PubMed, Haematologica) - "Not available."

Journal • P2 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. (PubMed, N Engl J Med) - P3 | "In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.)."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology

TRIMM-2: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (clinicaltrials.gov) - P1 | N=290 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Apr 2027 ➔ Dec 2027

Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. (ASCO 2023) - P1b/2, P2b, P3 | " We analyzed the effectiveness of non-cellular αBCMA (NCA) therapies in pts with MM treated in 4 clinical studies (STORM [NCT02336815]; STOMP [NCT02343042]; BOSTON [NCT03110562], XPORT-MM-028 [NCT04414475]) with selinexor + dexamethasone (Xd), with or without PIs, IMiDs, or αCD38 mAbs, followed by therapy with NCA...Thirty-seven pts (median age: 68, range: 40-87) received NCA therapy at any time following a selinexor regimen (Xd, n = 12; Xd + bortezomib, n = 9; Xd + pomalidomide, n = 6; Xd + daratumumab, n = 3; Xd + carfilzomib, n = 5; Xd + ixazomib, n = 2). NCAs included the ADC belantamab mafodotin (n = 28), the BiS teclistamab (n = 2), SEA-BCMA (n = 2), AMG 701 (n = 1), elranatamab (n = 1), MEDI2228 (n = 1), and investigational (n = 3; 2 had αBCMA bispecific antibodies and 1 had αBCMA BITE) (1 pt received 2 NCAs, belantamab and teclistamab)... In this cohort of heavily-pretreated pts with MM who received a selinexor regimen prior to NCA, overall..."

Hematological Malignancies • Immune Modulation • Multiple Myeloma • Oncology

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: Janssen Research & Development, LLC | Trial completion date: Jan 2029 ➔ Jun 2029

Trial completion date • Amyloidosis • Hematological Malignancies • Multiple Myeloma • Oncology • Smoldering Multiple Myeloma

Safety of Concurrent Systemic Therapy and Palliative Radiation in Multiple Myeloma (ASTRO 2026) - "For neutropenia, 11/12 had RT to active marrow (10 axial); agents included targeted [daratumumab (8% of drug exposures), lenalidomide (8%), bortezomib (9%), pomalidomide (10%), carfilzomib (7%)], cytotoxic chemotherapy (68%) and teclistimab (33%). Among this cohort, CCRT toxicities caused no unintended treatment breaks. Grade 3 SAEs were mainly hematologic. Given frequent need for palliative RT in MM, these data suggest it is reasonable to consider CCRT with close hematologic monitoring."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

Beneath the Ulcer: Uncovering Gastrointestinal AL Amyloidosis (ACG 2026) - "Case Description/ 50 year-old woman with kappa light-chain multiple myeloma and heart failure with reduced ejection fraction presented with epigastric and substernal pain.No NSAID use expect aspirin 81mg was reported. Multiple myeloma was well controlled on daratumumab and pomalidomide with stable serial bone marrow biopsies...She was started on pantoprazole 40 mg twice daily...(b) Surveillance endoscopy demonstrating a single large deep ulcer with a flat pigmented spot (Forrest IIC), with no interval healing despite prolonged high-dose proton pump inhibitor therapy. (c) Subsequent endoscopy with endoscopic ultrasound (EUS) showing interval improvement of the previously non-healing ulcer, now appearing as a 10 mm linear erosion."

Amyloidosis • Cardiovascular • Congestive Heart Failure • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Malignancies • Multiple Myeloma • Peptic Ulcer

Diffuse Colonic Ulcerations and Hematochezia Mimicking Ischemic Colitis in a Post-Hematopoietic Cell Transplant Patient With Strongyloides stercoralis Infection (ACG 2026) - "Case Description/ A 69-year-old male with IgA Kappa MM status post autologous HCT receiving daratumumab, pomalidomide, and dexamethasone presented with progressive weakness and failure to thrive over several months...Figure: Figure 1: Colonoscopy demonstrating erythema and ulceration at the hepatic flexure. Figure: Figure 2: Colonic biopsy demonstrating parasitic organisms (arrows) within the mucosa, with associated eosinophilic inflammation and giant cells involving the crypts and lamina propria."

Clinical • Atrial Fibrillation • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hypotension • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Multiple Myeloma • Transplantation

Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3 (ASH 2025) - P3 | " Eligible pts had 1-3 prior LOTs including a PI and lenalidomide (Len; pts with 1 prior LOT must have been Len-refractory) with progressive disease (PD) on or after the last LOT. We demonstrate the clinically remarkable and statistically significant PFS and OS benefits of Tec-Dara vs SoC triplets in RRMM, with 83.4% of Tec-Dara pts alive and progression-free at 3 yrs. Infections with Tec-Dara were well managed with established protocols. This highly effective, off-theshelf, immunotherapy combination represents a new SoC for RRMM as early as first relapse."

Clinical • IO biomarker • Late-breaking abstract • P3 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Plasmacytoma

Current Paradigm Shift in the Treatment of Hereditary Hemorrhagic Telangiectasia: A Narrative Review. (PubMed, Cerebrovasc Dis) - "Antiangiogenic agents including intravenous bevacizumab, pomalidomide, thalidomide, and oral pazopanib have demonstrated efficacy in reducing bleeding severity, improving hemoglobin levels, and decreasing transfusion requirements in moderate-to-severe disease. Advances in antiangiogenic and precision-medicine approaches are improving bleeding control and long-term outcomes. Early recognition, comprehensive screening, individualized therapy, and coordinated management across specialties are critical for optimizing care in this complex multisystem disease."

Journal • Review • Cardiovascular • CNS Disorders • Gastroenterology • Hematological Disorders • ACVRL1 • ALK1 • ENG • SMAD4 • TGFB1

Whole Proteome Analysis of Multiple Myeloma Patient Samples Provides New Insights into IMiD/CELMoD Resistance (IMS 2026) - " We analysed proteomic changes associated with relapse on lenalidomide (Len) therapy using paired baseline and relapse CD138+ samples from patients enrolled in the Myeloma XI trial. In a separate analysis we explored degradation profiles in patient MM cells (CD138+ samples from IMiD sensitive and resistant patients) treated ex vivo with IMiDs/CELMoDs (Len 10uM, pomalidomide [Pom] 10uM, iberdomide [Iber] 1uM and/or mezigdomide [Mezi] 1uM vs DMSO control over 4h)... Exploring the whole proteome of primary patient samples enhances our understanding of mechanisms of resistance and has highlighted potential novel therapeutic targets in IMiD resistance such as CTAG1B/CTAG1A, for which TCR engineered T cells have been studied in solid tumours."

Clinical • Hematological Malignancies • Multiple Myeloma • Solid Tumor • CDC37 • CHAF1B • CRBN • CTAG1A • CTAG1B • DHFR • IKZF1 • NCAPD2 • SDC1

Evaluation of Patient-Reported Outcomes and Subgroup Analysis with Subcutaneous Isatuximab Delivered via On-Body Injector Compared with Intravenous Delivery from the Phase 3 IRAKLIA Trial (IMS 2026) - P3 | "Introduction: The phase 3 IRAKLIA trial (NCT05405166) assessed isatuximab (Isa) delivered subcutaneously (SC) via an on-body injector (OBI; Isa SC OBI) vs Isa administered intravenously (Isa IV), with pomalidomide and dexamethasone (Pd), in patients (pts) with relapsed/refractory multiple myeloma (RRMM). In satisfied and neutral pt subgroups, more Isa SC OBI pts reported positive experiences vs Isa IV pts. At EOT, pts perceived more benefits than disadvantages with Isa SC OBI than with Isa IV. Our findings support the feasibility of the OBI as a novel method for SC delivery of Isa, in line with results from the overall IRAKLIA cohort."

Clinical • P3 data • Patient reported outcomes • Hematological Malignancies • Multiple Myeloma

Patient-Reported Outcomes (PROs) of Teclistamab-Based Treatment (Tx) in Relapsed/Refractory Multiple Myeloma (RRMM) After 1-3 Lines of Therapy (LOT) (IMS 2026) - P3 | "Introduction: Significant PFS and OS benefits were seen with teclistamab + daratumumab (Tec-Dara) in MajesTEC-3 (NCT05083169) and Tec monotherapy in MajesTEC-9 (NCT05572515) vs controls ( Dara + dexamethasone [dex] + pomalidomide/bortezomib [DPd/DVd] in MajesTEC-3; pomalidomide + bortezomib + dex or carfilzomib + dex [PVd/Kd] in MajesTEC-9) in patients (pts) with RRMM and 1-3 prior LOT. Tec-Dara and Tec improved HRQoL and significantly prolonged time to symptom worsening vs controls. Building on transformative PFS, OS, and safety data, PROs support pt-relevant benefits, complementing improved pt experience with monthly dosing and steroid-sparing regimens. Findings reinforce Tec-based tx as SoC in 2L+ RRMM across practice settings."

Clinical • Patient reported outcomes • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Updated Safety of Isatuximab Subcutaneous At-Home Administration by On-Body Injector in Patients with Relapsed/Refractory Multiple Myeloma in the Phase 3 IRAKLIA Study (IMS 2026) - P3 | " In IRAKLIA, patients with RRMM aged ≥18 years with ≥1 prior line of therapy were randomly assigned 1:1 to Isa SC OBI ( 1400 mg; n=263 ) or Isa IV (10 mg/kg; n=268) weekly in Cycle (C)1, then every 2 weeks, + pomalidomide ( 4 mg/day, Day [D]1–21) + dexamethasone (40 mg [20 mg if aged ≥75 years] weekly) in 4-week cycles . Updated data from the ongoing IRAKLIA trial showed that at-home administration by an HCP is feasible and well tolerated. Median injection time and success rate are consistent with in-clinic use. These data support the safety of Isa SC OBI administration at home by an HCP in addition to in the clinic, enabling more flexible, accessible, and comfortable care for patients with multiple myeloma."

Clinical • P3 data • Hematological Disorders • Hematological Malignancies • Multiple Myeloma

Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (D) ± Pomalidomide (P) vs D Plus P and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3 (IMS 2026) - P3 | " Phase 3 study randomizing pts with RRMM and ≥1 prior LOT including lenalidomide (R) and a proteasome inhibitor 1:1:1 to Tal-DP, Tal-D, or DPd. Tal-DP and Tal-D demonstrated a significant PFS benefit vs DPd, clinically meaningful OS improvements and gr ≥3 infection rates similar to or lower than DPd. Tal was combinable, with low rates of tx d/c. Tal-D ± P represents a new standard of care for RRMM as early as 2L across all practice settings."

Clinical • P3 data • Ataxia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Movement Disorders • Multiple Myeloma • Otorhinolaryngology

Integrated Genomic and Transcriptomic Profiling Identifies Response-Associated Transcriptional Programs in Relapsed/Refractory Multiple Myeloma Treated with Inobrodib-Based Therapy (IMS 2026) - P2 | "Ino plus pomalidomide/dexamethasone (pom/dex) is under investigation in heavily pretreated relapsed/refractory multiple myeloma (RRMM), including patients refractory to proteasome inhibitors, anti-CD38 antibodies, IMiDs, and/or BCMA-targeted therapy (NCT07096778). These findings identify activated MYC/G2M/E2F transcriptional states linked to response to ino-pom-dex therapy, with suppression following ino treatment in vitro. The data support further investigation of integrated genomic and transcriptional biomarkers associated with sensitivity and resistance to ino-based therapy, including in patients previously exposed/refractory to second-generation IMiD Pom and BCMA-targeted therapies. Larger multimodal and correlative analyses with clinical outcomes and laboratory validation are ongoing."

IO biomarker • Hematological Malignancies • Multiple Myeloma • IL6 • KMT2C • KRAS • NRAS • SDC1 • STAT3 • TNFA • TP53

The Impact of Pomalidomide-Containing Induction on Stem Cell Mobilization and Engraftment in Newly Diagnosed Multiple Myeloma: A Single Center Experience (IMS 2026) - "While lenalidomide-based regimens have been associated with impaired hematopoietic stem cell (HSC) mobilization, clinical data regarding the potential impact of pomalidomide (POM)-containing induction on mobilization outcomes remains extremely limited... This retrospective cohort study analyzed consecutive NDMM patients who underwent HSC mobilization with high-dose cyclophosphamide (HD-CTX) plus pegylated granulocyte colony-stimulating factor (PEG G-CSF) at a single center between January 2023 and December 2025...However, patients in the POM group received a significantly higher number of plerixafor (PXF) doses (p=0.030)... POM-containing induction significantly reduces total CD34+ collection yields and increases PXF requirements. However, it does not preclude the successful harvest of the minimum HSC doses required for transplantation, nor does it compromise post-transplant engraftment. For patients receiving POM-based induction, a risk-adapted mobilization strategy..."

Clinical • Hematological Malignancies • Multiple Myeloma

Teclistamab Plus Daratumumab (Tec-Dara) Versus Real-World Physician'S Choice of Therapy for Relapsed/Refractory Multiple Myeloma: Comparative Effectiveness Based on an Indirect Treatment Comparison (IMS 2026) - P3 | "Introduction: Tec-Dara significantly improved progression-free (PFS) and overall survival (OS) vs standard-of-care (SoC; Dara + dexamethasone + pomalidomide or bortezomib [DPd/DVd]) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and 1-3 prior lines of therapy (LOTs), in the phase 3 MajesTEC-3 study (NCT05083169)...An external cohort was created from the US Flatiron Health database, including pts who met key MajesTEC-3 criteria such as 1-3 prior LOTs, including a PI and lenalidomide (pts with 1 prior LOT were lenalidomide refractory), no prior BCMA-exposure or anti-CD38 mAb refractoriness (N=4224 observations from 2959 pts [Jan-2016 – Oct-2025])... Using IPTW-adjusted indirect comparisons in a large US RW cohort, Tec-Dara outperformed rwPC across a broad range of regimens in real-world practice, with significant improvements in PFS, OS and TTNT. These findings extend MajesTEC-3 results beyond the trial setting and support Tec-Dara as a robust,..."

Clinical • HEOR • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma